- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03290846
Secretin Activates Human Brown Fat and Induces Satiation. (GUTBAT)
Secretin Increases Glucose Uptake in Human Brown Adipose Tissue and Induces Satiation.
15 healthy males will be studied with PET/CT, using FDG to investigate glucose metabolism, and radiowater to investigate perfusion. One scan will be performed in controlled cold exposure, to see whether subjects have cold activated brown adipose tissue. Two scans will be performed in room temperature conditions, where all subjects are blinded and randomised to receive placebo and secretin hydrochloride. PET/CT scans will be analysed blinded.
20 healthy males will also be studied with fMRI, in order to investigate brain activity responses to appetizing versus bland foods. This study will be conduced on the same patients as the PET/CT study, but additional subjects with same inclusion and exclusion criteria will be recruited. Two fMRI scans will be performed in room temperature conditions, where all subjects are blinded and randomised to receive placebo and secretin hydrochloride. fMRI scans will be analysed blinded.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The PET/CT study will consist of 15 healthy, normal weight males, between ages 18-65. A 2-hour oral glucose tolerance test is performed on screening day. Calorimetry data is collected at baseline (resting and fasting) condition.
Three PET/CT scans on three different days will be performed to all 15 study subjects. Radiowater (15O)-H2O is used to study perfusion and FDG ((F18)-FDG) to study glucose metabolism. After radiowater, PET data is collected from the neck area for 6 minutes. After FDG, PET data is collected for 40 minutes on the neck area, 15 minutes on the chest, 15 minutes on the abdomen and 15 minutes on the brain. Calorimetry is collected during the entire scan. Blood samples are collected during scans for metabolites and for a plasma activity curve.
One scan is performed during controlled, cold exposure. This is done to investigate, whether patients have cold activated brown adipose tissue. After this, subjects will undergo two room temperature condition scans on different days, where participants are single-blinded and randomised to receive placebo (saline) or secretin (secretin hydrochloride) infusions. All scans are done in fasting conditions. After subjects have fed at the PET centre, calorimetry data is collected on all days.
A full body MRI will be performed on a separate day with the Dixon-method.
After scanning visits, brown adipose tissue biopsies will be taken from volunteers by a plastic surgeon. These samples are analysed in Munich.
Dynamic scan data is analysed with the Carimas program, using Patlak plot. Analysis is performed blinded. Further statistics analysis is done with SPSS.
The fMRI study will consist of 20 healthy, normal weight males, between ages 18-65. Subjects who underwent PET/CT scanning will be recruited for this study, as well as an additional group of subjects with the same inclusion and exclusion criteria. A 2-hour oral glucose tolerance test is performed on screening day for additional subjcts.
Two fMRI scans are conducted in room temperature after overnight fast on separate days. Subjects are randomized and blinded to receive placebo and secretin hydrochloride on separate days. Data on brain activity while viewing appetizing versus bland food images is collected during scan. After scanning subjects are given a meal and then followed up for two hours. Data on subjective satiety will be collected with a visual analogue scale questionnaire on nine different timepoints during the day: in preprandial, prandial and postprandial conditions.
Functional MRI data is analyzed with Matlab. Analysis is performed blinded. Satiety score is analzed with SPSS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Turku, Finland, 20521
- Turku PET Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy normal weight
Exclusion Criteria:
- cardiovascular disease, diabetes
- smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Secretin study
PET and MRI scannings will be performed twice.
Subjects will be given secretin hydrochloride and placebo on separate days.
In addition, subjects will undergo cold exposure PET scanning once.
|
Randomized, single-blinded secretin hydrochloride infusion.
Randomized, single-blinded saline infusion.
All subjects will undergo a cold exposure PET scan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secretin activates brown fat
Time Frame: Effect within one hour
|
Secretin increases brown adipose tissue glucose uptake compared to placebo.
This is studied with PET/CT, using a glucose tracer.
|
Effect within one hour
|
Secretin activates brown fat
Time Frame: Effect within six minutes
|
Secretin increases brown adipose tissue flow compared to placebo.
This is studied with PET/CT, using a radiowater tracer.
|
Effect within six minutes
|
Secretin induces satiation
Time Frame: Effect within one hour
|
Secretin attenuates brain activity, when subjects are viewing palatable vs. non-palatable food images.
|
Effect within one hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secretin increases whole body energy expenditure
Time Frame: Effect within two hours
|
Secretin increases whole body energy expenditure compared to placebo.
Data is collected durin PET/CT scans by indirect calorimetry.
|
Effect within two hours
|
Secretin induces satiety
Time Frame: Effect within three hours
|
Composite satiety score is measured by visual analogue scale questionnaire
|
Effect within three hours
|
Secretin reduces food consumption.
Time Frame: Within three days
|
Data on food consumption is collected directly after scan, as well as with food diaries.
Calory intake is measured and comparisons are made between secretin and placebo.
|
Within three days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secretin induces changes in biomarkers and metabolites.
Time Frame: Within two hours
|
Serum samples are collected during PET/CT scan and analyzed.
|
Within two hours
|
Brown adipose tissue biopsies.
Time Frame: Within 2 months
|
Brown adipose tissue biopsy samples are collected from subjects and analyzed.
|
Within 2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pirjo R Nuutila, MD,PhD, Turku UH
Publications and helpful links
General Publications
- Laurila S, Rebelos E, Lahesmaa M, Sun L, Schnabl K, Peltomaa TM, Klen R, U-Din M, Honka MJ, Eskola O, Kirjavainen AK, Nummenmaa L, Klingenspor M, Virtanen KA, Nuutila P. Novel effects of the gastrointestinal hormone secretin on cardiac metabolism and renal function. Am J Physiol Endocrinol Metab. 2022 Jan 1;322(1):E54-E62. doi: 10.1152/ajpendo.00260.2021. Epub 2021 Nov 22.
- Laurila S, Sun L, Lahesmaa M, Schnabl K, Laitinen K, Klen R, Li Y, Balaz M, Wolfrum C, Steiger K, Niemi T, Taittonen M, U-Din M, Valikangas T, Elo LL, Eskola O, Kirjavainen AK, Nummenmaa L, Virtanen KA, Klingenspor M, Nuutila P. Secretin activates brown fat and induces satiation. Nat Metab. 2021 Jun;3(6):798-809. doi: 10.1038/s42255-021-00409-4. Epub 2021 Jun 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T153/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Secretin Human
-
Johns Hopkins UniversityNational Cancer Institute (NCI); Lustgarten FoundationCompletedPancreatic Neoplasm | Peutz-Jeghers SyndromeUnited States
-
Orlando Health, Inc.ChiRhoClin, Inc.Not yet recruitingIrritable Bowel Syndrome | Abdominal Pain
-
Columbia UniversityWithdrawn
-
Elizabeth HechtCompletedPancreatic CancerUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
ChiRhoClin, Inc.Dartmouth-Hitchcock Medical CenterCompleted
-
Massachusetts General HospitalTerminatedChronic PancreatitisUnited States
-
Massachusetts General HospitalTerminatedIntraductal Papillary Mucinous NeoplasmsUnited States
-
Mayo ClinicCompleted
-
Indiana University School of MedicineRepligen Corporation; Shekhar, Anantha M.D., Ph.D.CompletedObsessive Compulsive Disorder (OCD)United States